Stockscreener 앱 받기
8.04
1.01%
0.08
시간 외 거래:
8.04
전일 마감가:
$7.96
열려 있는:
$7.97
하루 거래량:
175.58K
Relative Volume:
0.68
시가총액:
$253.99M
수익:
$128.45M
순이익/손실:
$6.54M
주가수익비율:
160.80
EPS:
0.05
순현금흐름:
$-8.79M
1주 성능:
-3.60%
1개월 성능:
+17.03%
6개월 성능:
+20.72%
1년 성능:
+70.34%
1일 변동 폭
$7.90
$8.205
1주일 범위
$7.87
$8.6299
52주 변동 폭
$3.6793
$8.6299
Lifecore Biomedical Inc Stock (LFCR) Company Profile
명칭
Lifecore Biomedical Inc
전화
(952) 368-4300
주소
3515 LYMAN BOULEVARD, CHASKA
LFCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
8.04 | 253.99M | 128.45M | 6.54M | -8.79M | 0.05 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 개시 | William Blair | Outperform |
| 2024-09-05 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
Lifecore Biomedical: Inflecting Financials Over Next 3 Years (NASDAQ:LFCR) - Seeking Alpha
Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy - Nasdaq
Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy By Investing.com - Investing.com South Africa
Lifecore signs 10-year manufacturing deal with key ophthalmic client By Investing.com - Investing.com Nigeria
Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore Biomedical Enters 10-Year Commercial Manufacturing & Supply Agreement with Existing Customer - Contract Pharma
2025-06-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect | NDAQ:LFCR | Press Release - Stockhouse
Lifecore signs 10-year manufacturing deal with key ophthalmic client - Investing.com
Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophth - GuruFocus
Lifecore Biomedical Signs 10-Year Manufacturing, Supply Deal With Ophthalmic Therapy Customer - MarketScreener
Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophthalmic Therapy | LFCR Stock News - GuruFocus
Lifecore Biomedical Signs 10-Year Commercial Manufacturing Agreement to Advance Novel Ophthalmic Therapeutic - Nasdaq
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer - GlobeNewswire
Lifecore Biomedical Lands Multi-Million Dollar, 10-Year Manufacturing Contract for Novel Eye Treatment - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Purchased by Bank of America Corp DE - Defense World
Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lifecore receives early $10 million payment for equipment sale By Investing.com - Investing.com South Africa
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale - GlobeNewswire
Lifecore Receives Full Payment Early For $17 Mln Equipment Sale - Nasdaq
Lifecore Biomedical Receives Remaining $10 Million for Sale of Isolator Filler Ahead of Schedule - marketscreener.com
Lifecore (LFCR) Completes $10 Million Equipment Sale Payment | LFCR Stock News - GuruFocus
Lifecore receives early $10 million payment for equipment sale - Investing.com Australia
Lifecore Biomedical Fast-Tracks $10M Equipment Payment as New Filler Promises $300M Revenue Potential - Stock Titan
2025-06-10 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse
Squarepoint Ops LLC Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
(LFCR) Long Term Investment Analysis - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Contrasting Lifecore Biomedical (NASDAQ:LFCR) & Liquidia (NASDAQ:LQDA) - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago - Yahoo Finance
How the (LFCR) price action is used to our Advantage - news.stocktradersdaily.com
Lifecore appoints new chief commercial officer to drive growth By Investing.com - Investing.com South Africa
Lifecore Biomedical Appoints CCO - Contract Pharma
Lifecore Biomedical Names Mark Dafonseca Chief Commercial Officer - marketscreener.com
LFCR Appoints New Chief Commercial Officer | LFCR Stock News - GuruFocus
Lifecore appoints new chief commercial officer to drive growth - Investing.com
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer - GlobeNewswire
Lifecore Biomedical Taps 30-Year Pharma Veteran as CCO to Accelerate CDMO Market Expansion - Stock Titan
Northern Trust Corp Purchases 28,019 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Analysts Set Expectations for LFCR Q4 Earnings - Defense World
William Blair Begins Coverage on Lifecore Biomedical (NASDAQ:LFCR) - Defense World
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies? - Insider Monkey
Lifecore Biomedical (LFCR) Receives 'Outperform' Rating from Wil - GuruFocus
Lifecore stock gains on Outperform rating by William Blair - Investing.com Canada
Lifecore Biomedical Inc (LFCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lifecore Biomedical Inc 주식 (LFCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| English Aron R. | 10% Owner |
May 28 '25 |
Sale |
7.12 |
150,419 |
1,071,555 |
264,180 |
| English Aron R. | 10% Owner |
May 23 '25 |
Sale |
6.75 |
96,137 |
649,386 |
1,554,103 |
| English Aron R. | 10% Owner |
May 13 '25 |
Sale |
7.00 |
12,334 |
86,353 |
1,650,240 |
| English Aron R. | 10% Owner |
May 12 '25 |
Sale |
7.03 |
45,698 |
321,426 |
1,662,574 |
| English Aron R. | 10% Owner |
May 08 '25 |
Sale |
7.00 |
5,098 |
35,693 |
1,708,972 |
| English Aron R. | 10% Owner |
May 09 '25 |
Sale |
7.00 |
700 |
4,900 |
1,708,272 |
| English Aron R. | 10% Owner |
May 05 '25 |
Sale |
7.08 |
24,543 |
173,831 |
1,730,618 |
| English Aron R. | 10% Owner |
May 07 '25 |
Sale |
7.01 |
15,847 |
111,099 |
1,714,070 |
| English Aron R. | 10% Owner |
May 06 '25 |
Sale |
7.05 |
701 |
4,940 |
1,729,917 |
| Josephs Paul | Chief Executive Officer |
Jan 08 '25 |
Buy |
5.74 |
17,000 |
97,580 |
559,717 |
2.01%
0.40%
자본화:
|
볼륨(24시간):